Poster

Medication Adherence and Healthcare Resource Utilization in South Carolina Medicaid Beneficiaries with Schizophrenia or Schizoaffective Disorder: Long-acting Injectable vs. Oral Antipsychotics

Abstract: Background: Schizophrenia requires long-term treatment with antipsychotics; however, poor adherence to antipsychotic treatment can result in increased healthcare resource utiliz...

08/20/2024

Transitioning Patients to Long-Acting Injectable Antipsychotics: Attitudes and Perceptions of US Clinicians Based on a Hypothetical Case (Results from the DECIDE Survey)

Abstract: Background: Treatment with long-acting injectable antipsychotics (LAIs) reduces relapses in schizophrenia; however, best practices for introducing and transitioning patients to ...

08/20/2024

Patient Outcomes Post Hospitalization Discharge Among Patients With Schizophrenia Treated With a Long Acting Injectable or Switched to a New Oral Antipsychotic Medication

Abstract: Background: Low adherence to antipsychotic medication following a hospital discharge among patients with schizophrenia can lead to a higher risk of relapse and greater health ca...

08/20/2024

TV-46000—a Long-Acting Subcutaneous Antipsychotic (LASCA) for the Treatment of Schizophrenia: Local Tolerability and Injection Site Reactions

Abstract: Background: The phase 3 schizophrenia program for TV-46000, a long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone, included the RISE efficacy study (NCT035...

08/20/2024

Patient Satisfaction With the Deutetrabenazine 4-week Patient Titration Kit: Interim Results of the
START Study

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-rela...

08/20/2024

Patients With Tardive Dyskinesia at Risk for Drug-Drug Interactions With Vesicular Monoamine Transporter 2 Inhibitors Across Age Groups, Underlying Psychiatric Conditions, and Payer Types

Abstract: Background: Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are indicated for treatment of adults with tardive dyskinesia (TD). Valbenazine label...

08/20/2024

Preferences for Selecting and Initiating Long-Acting Injectable Antipsychotics: A Survey of US Psychiatric Clinicians (Results from the DECIDE Survey)

Abstract: Background: Although long-acting injectable antipsychotics (LAIs) improve adherence and reduce schizophrenia relapse rates, they remain underutilized in clinical practice. Meth...

08/20/2024

Real World Effectiveness of Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-rela...

08/20/2024

Real-World Use of Esketamine Nasal Spray at 46 Months: Characterizing Healthcare Settings, Prescribers, Pharmacies, Patients, and Key Safety Data

Abstract: Background: Upon approving esketamine nasal spray (ESK) in conjunction with an oral antidepressant for treatment-resistant depression in adults, the FDA required a Risk Evaluati...

08/20/2024

Global Improvements and Psychiatric Stability in Adults with Tardive Dyskinesia and Mood Disorder: Post Hoc Analyses of Two Long-Term Valbenazine Studies

Abstract: Background: Effective and comprehensive treatment of tardive dyskinesia (TD) requires reducing patients’ abnormal involuntary movements while maintaining their psychiatric stabi...

08/20/2024